Warfarin use among older atrial fibrillation patients with non–ST-segment elevation myocardial infarction managed with coronary stenting and dual antiplatelet therapy
Emil Loldrup Fosbøl(University of Copenhagen), Eric D. Peterson(The University of Texas Southwestern Medical Center), Laine Thomas(Duke University), Roger M. Mills(Janssen (Belgium)), Matthew T. Roe(Clinical Research Institute), Renato D. Lópes(Duke University), Shuang Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Winslow Klaskala(Johnson & Johnson (United States)), Tracy Y. Wang(Clinical Research Institute), Jonathan P. Piccini(Clinical Research Institute)
Cited by 49
Related Papers
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
|New England Journal of Medicine|2011|9.4k
An Updated Definition of Stroke for the 21st Century
|Stroke|2013|3.5k
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
|The Lancet|2018|1.8k
AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update
|Circulation|2011|1.8k
2023 ESC Guidelines for the management of endocarditis
|European Heart Journal|2023|1.6k